Taichu Biotechnology
Integrated CRO and CDMO biopharmaceutical technology platform
About Taichu Biotechnology
Taichu Biotechnology, established in 2020, is a biopharmaceutical company headquartered in Shanghai, China, that provides an integrated service model combining contract research organization (CRO) and contract development and manufacturing organization (CDMO) capabilities. The company specializes in offering end-to-end technical solutions for innovative drug development, from early-stage discovery to preclinical research. The business was founded by Dr. Jing Ma, who serves as the Chairman and CSO.
The company's business model is structured to streamline R&D workflows and accelerate therapeutic advancement for its global partners. It operates through several wholly-owned subsidiaries, including Taichu Bio (non-clinical CRO), Tarlead Biologics (antibody drug CDMO), TJR Bio (oligonucleotide R&D and manufacturing), and a joint venture, AceMab Ltd. (fully humanized antibody platform). This structure creates a comprehensive service ecosystem designed to bridge the gap between drug discovery and commercialization. Its services cover non-clinical drug safety evaluations, pharmacodynamic and pharmacokinetic studies, antibody drug process development, and manufacturing. The company serves a client base of approximately 630 pharmaceutical companies and organizations.
Taichu Biotechnology has raised significant capital to support its growth, including a Series A funding round of CNY 400 million (USD 59 million) in May 2023 and a Series B round in March 2025. Its investors include notable firms such as IDG Capital, TAILONG VC, Fortera Capital, and TigerYeah Capital.
Source: Dealroom company dataNews
Open roles
Taichu Biotechnology in the Huangpu ecosystem
The Taichu Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Yijing Capital
Apricot Capital- JCJuntong Capital
Shanghai Science and Technology Innovation Center
Suzhou Zhongxin Innovation Capital
SHC Shanghai Biomedical Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Taichu Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Taichu Biotechnology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

